Mujagić H, Kolarić K, Malenica B, Nola P
Biomedicine. 1979 Jun;30(2):95-102.
Eighteen patients with histologically confirmed metastatic malignant melanoma were treated with intradermal BCG. Before starting immunotherapy their immunocompetence was tested in vivo and in vitro. Four of 15 (27%) achieved complete regression, and two (13%) a regression of more than 50%, after systemic BCG. All three patients treated with perinodular injection of BCG had complete regression of treated as well as some of untreated nodules. Treatment was unsuccessful in 9 patients. Five of them (33%) had a disease stabilisation for more than 5 months. The results of BCG immunotherapy were compared with those of chemotherapy alone. The immunotherapy patients had longer remissions and survived longer than those treated by chemotherapy. All patients had repeat skin tests with PPD after BCG but showed no significant improvement in tuberculin reactivity. Despite, their clinical condition often being improved after BCG. We conclude that BCG may be of considerable benefit to malignant melanoma patients.
18例经组织学确诊的转移性恶性黑色素瘤患者接受了皮内注射卡介苗治疗。在开始免疫治疗前，对他们的免疫能力进行了体内和体外测试。15例患者中有4例（27%）在全身注射卡介苗后实现了完全缓解，2例（13%）缓解超过50%。所有3例接受卡介苗结节周围注射治疗的患者，其治疗的结节以及部分未治疗的结节均实现了完全缓解。9例患者治疗失败。其中5例（33%）病情稳定超过5个月。将卡介苗免疫治疗的结果与单纯化疗的结果进行了比较。接受免疫治疗的患者比接受化疗的患者缓解期更长，生存期也更长。所有患者在卡介苗治疗后均用结核菌素纯蛋白衍生物进行了重复皮肤试验，但结核菌素反应性未见明显改善。尽管如此，卡介苗治疗后他们的临床状况通常有所改善。我们得出结论，卡介苗可能对恶性黑色素瘤患者有相当大的益处。
